Keine Story von Amgen Europe GmbH mehr verpassen.

Amgen Europe GmbH

  • 15.11.2011 – 15:32

    Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union

    Thousand Oaks, California, November 15 (ots/PRNewswire) - Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix(R) (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in ...